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OBJECTIVES The goals of this study were to assess late clinical outcome and left ventricular ejection
fraction (LVEF) after transmyocardial revascularization with CO2 laser (TMR).
BACKGROUND During the 1990s TMR emerged as a treatment option for patients with refractory angina not
eligible for conventional revascularization. Few reports exist on clinical effects and LVEF 3
years after TMR.
METHODS One hundred patients with refractory angina not eligible for conventional revascularization
were block-randomized 1:1 to receive continued medical treatment or medical treatment
combined with TMR. The patients were evaluated at baseline and after 3, 12 and 43 (range:
32 to 60) months with end points to angina, hospitalizations due to acute myocardial
infarctions or unstable angina, heart failure and LVEF. Mortality was registered and MOS
36 Short-Form Health Survey answered at baseline and after 3, 6 and 12 months.
RESULTS Forty-three months after TMR, angina symptoms were still significantly improved, and
unstable angina hospitalizations reduced by 55% (p  0.001). Heart failure treatment (p 
0.01) increased, whereas the number of acute myocardial infarctions, LVEF and mortality
was not affected. Quality of life was improved 3, 6 and 12 months after TMR.
CONCLUSIONS Forty-three months after TMR, angina symptoms and hospitalizations due to unstable
angina were significantly reduced, heart failure treatment increased and LVEF and mortality
were seemingly unaffected. (J Am Coll Cardiol 2002;39:1588–93) © 2002 by the American
College of Cardiology Foundation
During the 1990s transmyocardial revascularization with
CO2 laser (TMR) emerged as treatment in patients with
severe angina pectoris not amenable for conventional revas-
cularization (1–3). Transmyocardial revascularization with
CO2 laser is performed by making channels directly through
the left ventricular wall with laser energy release (4) and a
usual approach through a left anterior thoracotomi. From
randomized clinical trials, symptomatic relief has been
reported until one year after TMR (5–10). The mechanism
is not understood, but angiogenesis, denervation and pla-
cebo have been suggested as possible explanations. Clinical
and mortality data from randomized clinical studies more
than one year after TMR have not been published. Early
reduction of global left ventricular function has been re-
ported (11–15), but the effect on left ventricular function in
the long run is unknown. We evaluated angina symptoms,
hospitalizations and left ventricular ejection fraction
(LVEF) three to five years after TMR, quality of life during
(QoL) the first year and registered mortality.
METHODS
Design and study population. The study is a late
follow-up of the Norwegian Randomized trial with CO2
laser (9) in which 100 eligible patients were block-
randomized 1:1 between November 1995 and January 1998
to achieve either continued optimal medical treatment alone
(MT group) or in combination with TMR (TMR group) in
a noncrossover design. Included were patients suffering
from angina pectoris New York Heart Association (NYHA)
functional class III or IV despite optimal medical treatment,
who were not candidates for percutaneous transluminal
coronary angioplasty or coronary artery bypass grafting
because of diffuse and peripheral coronary artery disease and
who were willing to participate in a randomized study.
Exclusion criteria were age 75 years; LVEF 30%;
nondemonstrated reversible ischemia as assessed by exercise
electrocardiogram, dobutamine stress echocardiography
(DSE) or rest/stress technetium 99m-tetrofosmin myocar-
dial perfusion scan (SPECT); overt heart failure and inabil-
ity to undergo study tests and conditions precluding thoracic
surgery. Clinical status and assessments of LVEF were, in
the initial study, performed before randomization and after
3 and 12 months. Transmyocardial revascularization with
CO2 laser has not been offered as treatment against refrac-
tory angina in Norway except in clinical trials. After the
From the *Department of Cardiology, †Department of Clinical Chemistry/Section
of Nuclear Medicine and ‡Department of Psychiatry, Rikshospitalet University
Hospital, Oslo; §Feiringklinikken, Feiring, Oslo, Norway; and Ullevaal University
Hospital, Oslo, Norway. Supported by the Norwegian Ministry of Health and Social
Affairs.
Manuscript received October 15, 2001; revised manuscript received February 21,
2002, accepted February 22, 2002.
Journal of the American College of Cardiology Vol. 39, No. 10, 2002
© 2002 by the American College of Cardiology Foundation ISSN 0735-1097/02/$22.00
Published by Elsevier Science Inc. PII S0735-1097(02)01828-4
initial 12 months follow-up, the patients were controlled by
their general practitioners or local hospitals. A late
follow-up was performed after 43 (range: 32 to 60) months.
At baseline, 71% of the patients were classified as angina
NYHA functional class III and 29% as NYHA functional
class IV patients. Baseline patient characteristics (Table 1)
and medications did not differ between the treatment
groups. During surgery, one patient was found to have a
graftable left anterior descending coronary artery that had
not been detected by coronary angiography and was ex-
cluded from follow-up analysis. Data were collected from
November 2000 until September 2001. One patient in the
MT group was not available for assessment. Otherwise,
complete clinical data were obtained from all. All patients at
baseline and 84% of patients alive at late follow-up had a
multiple-gated acquisition (MUGA) performed. No cross-
over occurred between the treatment groups. The scientific
protocol was approved by the regional ethics committee.
Surgery. In a combined general and thoracic epidural
anesthesia and without the use of cardiopulmonary bypass
(9) or intra-aortic balloon pump prophylactically, we treated
the patients by use of an 800-W CO2 laser (The Heart
Laser, PLC Medical Systems, Inc., Milford, Massachu-
setts). The channels were made directly through the left
ventricular wall on the beating heart through a left anterior
thoracotomy with pulses synchronized with R-wave in the
electrocardiogram. The vascular territories to be treated
were defined on basis of DSE and SPECT results, and
about one channel per cm2 of presumed ischemic and viable
myocardium was made. An average of 48 (standard devia-
tion  7) channels (energy range: 30 J to 50 J) were made.
Channel formation was confirmed through a 5-MHz mul-
tiplane ultrasound transesophageal probe (VingMed,
Horten, Norway).
Measurements. CLINICAL DATA. Clinical information was
retrieved with respect to severity of angina symptoms,
hospitalizations due to unstable angina, myocardial infarc-
tions, heart failure or other reasons, repeated coronary
angiography or coronary interventions, current medications
and smoking habits. Clinical assessments were done using
standardized telephone interviews. The information was
checked against hospital records and the patients’ general
practitioners, as was information about causes of death.
“Probably cardiac related causes” of death included patients
who died from clinically diagnosed heart failure or acute
myocardial infarction or who died suddenly. Only the
patients who died early postoperatively had an autopsy
performed. Before the interviews, data from the National
Health Security system were used to update patient infor-
mation with respect to mortality and time of death. Angina
was classified according to the NYHA classification system
and was assessed unblinded by one investigator after stan-
dardized interviews about symptoms related to graded
activities at baseline and follow-up interviews. A change of
two or more angina functional classes was considered
clinically significant (6).
MUGA. Investigations were performed consecutively follow-
ing randomization numbers at Section of Nuclear Medicine,
Rikshospitalet University Hospital, and the operators were
blinded to clinical patient information. The LVEF refer-
ence interval at rest has been established to be 50% to 78%
and the standard deviation for same-day repeated measure-
ments 2.1% points (12).
QOL. MOS 36 Short-Form Health Survey (SF-36) is a
generic questionnaire consisting of 36 questions about the
subscales physical functioning, role-physical (role limita-
tions because of physical health problems), body pain,
general health, vitality, social functioning, role-emotional
(role limitations because of emotional problems) and mental
health. A summary physical component scale (PCS) and
summary mental component scale (MCS) is computed for
the individual patient at each time point. Scoring and
interpretation is performed as described by Ware et al. (16).
The results are presented in a 100 point scale where 100 is
the best and 0 the worst possible score. Summary physical
Abbreviations and Acronyms
DSE  dobutamine stress echocardiography
LVEF  left ventricular ejection fraction
MCS  summary mental component scale
MT  medical treatment
MUGA  multiple-gated acquisition
NYHA  New York Heart Association
OBL  baseline outcome variable
OFU  follow-up outcome variable
PCS  summary physical component scale
QoL  quality of life
SF-36  MOS 36 Short-Form Health Survey
SPECT  technetium 99m-tetrofosmin myocardial
perfusion scan
TMR  transmyocardial revascularization with
CO2 laser
Table 1. Patient Characteristics at Baseline
Characteristics
MT Group
(n  50)
TMR Group
(n  49)
Age (yrs), mean  SD 64  8.1 61  8.5
Women (%) 12 16
Diabetes mellitus (%) 28 22
Treatment for hypertension (%) 28 28
Treatment for hypercholesterolemia (%) 82 76
Current smokers (%) 32 24
Peripheral arteriosclerosis (%) 36 30
Cerebrovascular disease (%) 14 8
Three-vessel disease (%) 94 88
Left main stenosis (%) 32 24
Patients with previous MI (%) 70 70
Patients with previous
revascularizations (%)
92 90
LVEF (%) 49.6  11.9 48.9  11.9
Cerebrovascular disease  history of cerebrovascular episodes; LVEF  left ventric-
ular ejection fraction; MI  myocardial infarction; MT  medical treatment;
peripheral arteriosclerosis  symptoms of peripheral arteriosclerosis; TMR 
transmyocardial revascularization with CO2 laser.
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component scale and MCS changes of three or more points
are considered clinically relevant (17). The questionnaire
was answered by the patients before randomization and after
3, 6 and 12 months. To assess the robustness of the angina
scoring, we compared the mean scores between patients
assessed to be in different angina functional classes. The
Norwegian version of the SF-36 has been validated, and
normative data from the Norwegian population have been
presented (18).
Statistics. Results are given as mean SD, median (range)
or frequency (%). The relative changes of the outcome
variables between baseline (OBL) and follow-ups (OFU)
were estimated for each patient: RC  [OBL  OFU/OBL]
 100. The evaluation of efficacy of TMR was done by
comparing the treatment groups with respect to relative
changes from baseline to follow-up for each outcome
variable. Normal distribution was evaluated by visual eval-
uation of the histograms of the end point variables and by
performing the one sample Kolmogorow-Smirnov
goodness-of-fit test. The data on SF-36 showed approxi-
mation of the distribution to the Gaussian curve, and
parametric tests were used to compare baseline values and
relative changes between the two groups and the mean of
scores between the individual angina functional classes (t
test). The data on LVEF were normally distributed but
showed heterogeneity of the variance in the two groups, and
comparisons were done using the Mann-Whitney U non-
parametric test. The chi-square test was used to test
significance level for frequency differences. Significance level
was defined as p  0.05 (19).
RESULTS
Clinical outcome and mortality. Median follow-up was
43 (range: 32 to 60) months. Total mortality was 23%
(included 4% postoperative mortality) and was not different
between the groups (Table 2). Six patients in each treatment
group died from “probably cardiac related causes.” A signif-
icant improvement in angina symptoms was still present
three to five years after TMR (Table 2), and fewer hospi-
talizations due to unstable angina were registered. Antian-
ginal medication was, however, only insignificantly reduced
(Table 3) compared with the MT group. A higher number
of hospitalizations due to heart failure (p  NS) and an
increased use of diuretics and angiotensin-converting en-
zyme inhibitors was observed (p  0.002) in the TMR
group (Table 3) compared with the MT group.
LVEF (MUGA). Due to health problems, 12 patients were
not able to meet for investigation. The analysis was based on
33 patients in the TMR group and 30 patients in the MT
group who had complete MUGA investigations at baseline
and follow-ups. After TMR, a reduction in LVEF was
observed after 3 months (p 0.05) compared with baseline,
whereas the differences were not significant after 12 months
and at late follow-up, and the changes were not significantly
different from the changes in the MT group (Fig. 1) at any
time.
QoL. The physical health subscales and PCS of SF-36
were significantly improved after TMR (Fig. 2), whereas the
mental and social subscales and MCS did not change
significantly. The mean summary PCS scores were clinically
and statistically different between patients classified into
angina functional class IV, class III and class II at each time
point, whereas the difference between functional class I and
class II was not significant (Fig. 3). The mean summary
MCS were not different between the patients in the respec-
tive angina functional classes.
DISCUSSION
A reduction in angina symptoms could still be observed
three to five years after TMR. The lower number of
hospitalizations due to unstable angina comply with a
continued antianginal effect from TMR. This was, however,
Table 2. Late Clinical Effects and Smoking Habits 43 (Range: 32 to 60) Months After TMR
MT Group TMR Group
p Value*
Baseline
(n  50)
Follow-Up
(n  37)
Baseline
(n  49)
Follow-Up
(n  38)
Died before late follow-up (%) 24 % 22 % NS
Angina class
NYHA functional class IV (%) 24 27 34 18
NYHA functional class III (%) 76 78 66 13
NYHA functional class II (%) 0 16 0 39
NYHA functional class I (%) 0 0 0 21
Angina improvement
2 NYHA functional classes (%) 3 24* 0.001
1 NYHA functional classes (%) 24 61* 0.010
Hospitalizations during follow-up, all (n) 181 138 NS
AMI (n) 12 8 NS
Unstable angina (n) 95 53* 0.047
Heart failure (n) 11 19 NS
Current smokers (%) 18 16 NS
*Significance level between the groups.
AMI  acute myocardial infarction; MT  medical treatment; NYHA  New York Heart Association; TMR 
transmyocardial revascularization with CO2 laser.
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not followed by a significant reduction in antianginal
medication. An increased use of heart failure medication
(p  0.01) was registered, whereas the number of hospital-
izations due to heart failure was not significantly higher than
in the MT group. No late changes in LVEF or mortality
were observed between the treatment groups during follow-
up. However the study was not designed to assess mortality
and should be interpreted as such.
The antianginal effect of TMR at late follow-up in this
study is consistent with reports from observational studies
(4,20,21), whereas late follow-up data have not been pub-
lished from randomized clinical trials. The improved QoL
during the first 12 months after TMR complies with the
improved QoL reported from other randomized studies as
well (5,6). Angina classification is a soft parameter in the
evaluation of treatments in coronary heart disease. Classifi-
cation may vary between observers and may be affected by
patient as well as doctor bias in unblinded studies (5,6). To
evaluate the angina classifications, we compared NYHA
classification and SF-36 PCS and MCS scores. The PCS
scores were significantly different between patients classified
into NYHA functional class II, III and IV, respectively,
with the lower score in NYHA functional class IV patients,
intermediate score in NYHA functional class III patients
and higher score in NYHA functional class II patients. No
significant differences were observed between NYHA func-
tional class II and NYHA functional class I patients or with
respect to MCS score. In summary, the assessment of
angina complies with physical components of QoL assessed
by SF-36.
The fewer hospitalizations due to unstable angina in the
TMR group were statistically significant compared with the
MT group after 43 (range: 32 to 60) months but not after
12 months (9). Late biologic effects could explain differ-
ences. However, differences may as well be explained by the
close contact between the patients and the hospital person-
nel during the first year, whereas this was not the situation
thereafter.
Perioperative mortality has been reported as quite high in
some studies (20,22,23) and has not encouraged the use of
TMR in high-risk patients. Proper patient selection and
perioperative care have reduced risk and mortality
(14,15,24). Our selection criteria were based on clinical
experience available in the literature until 1995 and excluded
high-risk patients who might have benefited more from
TMR (age  75 years, LVEF  30% or unstable angina)
(7,14). Scarring and silent ischemia may be substrates for
arrhythmias and sudden death, and the extensive use of
beta-blockers in both groups may have contributed to the
low overall mortality. An increased incidence of clinical
heart failure after TMR is reported in our study. Early
detrimental effect on left ventricular function and heart
failure has been described after TMR (11,14,15). Early and
late detrimental effects on LVEF have been reported three
months (5) and three years after TMR (20), and a recently
published stress echocardiography study (13) indicated a
deterioration after three months. We were not able to detect
late differences with respect to LVEF in the present study.
A high number of channels were made in our study, and the
Table 3. Drug Treatment Baseline and at Late Follow-Up (32 to 60 Months)
MT Group TMR Group
p Value*
Baseline
(n  50)
Follow-Up
(n  37)
Baseline
(n  49)
Follow-Up
(n  38)
Beta-blockers (%) 92 92 98 82 NS
Calcium antagonists (%) 66 62 62 39 NS
Long-acting nitrates (%) 88 92 90 79 NS
Aspirin (%) 80 73 82 74 NS
Warfarin (%) 20 30 26 29 NS
ACE inhibitors (%) 30 43 24 48* 0.006
Statins (%) 86 84 82 82 NS
Diuretics (%) 24 24 26 47* 0.015
Insulin (%) 8 3 10 14 NS
Oral antidiabetics (%) 10 8 2 3 NS
*Significance between groups during follow-up.
ACE  angiotensin-converting enzyme; MT group  medical treatment; TMR  transmyocardial revascularization with
CO2 laser.
Figure 1. Left ventricular ejection fraction (LVEF) after transmyocardial
revascularization with CO2 laser compared with medical treatment. Left
ventricular ejection fraction in 63 of 75 patients (84%) with complete
multiple-gated acquisition investigations during follow-up; LVEF values
are given as mean  SD. No statistically significant difference between the
groups during follow-up. Black bar  TMR (n  33); lined bar 
medical treatment (n  30).
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increased use of heart failure medication could be explained
by diastolic dysfunction secondary to ischemia or laser
induced necrosis and fibrosis in the myocardium (25). No
report on late diastolic effects after TMR has been pub-
lished. Denervation could as well change symptoms from
angina into dyspnea to be misinterpreted as heart failure,
which eventually could explain much of the antianginal
effects.
Figure 2. Quality of life (MOS 36 Short-Form Health Survey) during 12 months’ follow-up. Summary physical component scale (PCS) and summary
mental component scale (MCS) in the medical treatment (MT) group and transmyocardial revascularization with CO2 laser (TMR) group during 12
months follow-up. Higher values indicate improved quality of life. *Statistical significance between groups, comparing the changes between the groups from
baseline to 3, 6 and 12 months, respectively.
Figure 3. Summary physical component scales (PCS) in patients with different angina classifications. Higher values indicate improved quality of life. Values
are given as mean  SD. *Statistical significance between patients classified as New York Heart Association (NYHA) functional class II and class III and
between NYHA functional class III and class IV. Lined bar  all; shaded bar  transmyocardial revascularization with CO2 laser; black bar  medical
treatment. *p  0.01.
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Study limitations. The results are based on a single center
study of a small patient population. The inclusion and
exclusion criteria excluded high-risk patients. Angina symp-
toms are a soft parameter and their assessment affected by
patient’s as well as doctor’s bias, and the results of this study
should be interpreted in light of this. A new perfusion scan
or DSE was not performed at late follow-up, and the study
gives no indication to whether improved myocardial perfu-
sion, placebo effects, denervation or other mechanisms are
operating.
Conclusions. Compared with a control group, angina
symptoms were still significantly improved three to five
years after TMR. An increased incidence of heart failure
seemed to occur, but no differences in LVEF or mortality
were registered.
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